Edwards Lifesciences Corporation (NYSE:EW) Q2 2019 Earnings Conference Call July 23, 2019 5:00 PM ET Company Participants Mark Wilterding - IR Mike Mussallem - Chairman and CEO Scott Ullem - CFO Conference Call Participants Bob Hopkins - Bank of America David Lewis - Morgan Stanley Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Joanne Wuensch - BMO Capital Markets Robbie Marcus - JPMorgan Cecilia Furlong - Canaccord Genuity Matt Taylor - UBS Matt Miksic - Credit Suisse Josh Jennings - Cowen & Comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ýQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 ...

Edwards Lifesciences Corporation (NYSE:EW) Q1 2019 Earnings Conference Call April 23, 2019 5:00 PM ET Company Participants Mike Mussallem - Chairman & CEO Scott Ullem - CFO Conference Call Participants Vijay Kumar - Evercore ISI David Lewis - Morgan Stanley Bob Hopkins - Bank of America Merrill Lynch Lawrence Biegelsen - Wells Fargo Chris Pasquale - Guggenheim Robbie Marcus - J.P. Morgan Rick Wise - Stifel Joanne Wuensch - BMO Capital Markets Jason Mills - Canaccord Genuity Matt Taylor - UBS Josh Jennings - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (St ...

| --- | --- | |-------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring | | Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences Corporation will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securit ...